Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.
Ten Hoorn S, Waasdorp C, van Oijen MGH, Damhofer H, Trinh A, Zhao L, Smits LJH, Bootsma S, van Pelt GW, Mesker WE, Mol L, Goey KKH, Koopman M, Medema JP, Tuynman JB, Zlobec I, Punt CJA, Vermeulen L, Bijlsma MF.
Ten Hoorn S, et al. Among authors: tuynman jb.
BMC Cancer. 2022 Apr 12;22(1):394. doi: 10.1186/s12885-022-09436-0.
BMC Cancer. 2022.
PMID: 35413826
Free PMC article.